Price T Rowe Associates Inc. MD Has $74.08 Million Holdings in Krystal Biotech, Inc. $KRYS

Key Points

• Price T Rowe Associates Inc. MD reduced its holdings in Krystal Biotech, Inc. by 19.4% to 410,861 shares, valued at approximately $74.08 million, according to the latest SEC filing.
• Analysts have mixed ratings on Krystal Biotech with an average target price of $210.38; recent reports have ratings ranging from a "Strong Buy" to "neutral" with price targets between $166.00 and $240.00.
• Insider Suma Krishnan sold 13,435 shares of Krystal Biotech for over $2 million recently, indicating a 0.92% decrease in their ownership of the stock.

Price T Rowe Associates Inc. MD decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 19.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 410,861 shares of the company's stock after selling 98,598 shares during the period. Price T Rowe Associates Inc. MD owned 1.42% of Krystal Biotech worth $74,079,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KRYS. Envestnet Asset Management Inc. lifted its position in Krystal Biotech by 1.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after acquiring an additional 121 shares during the last quarter. Marshall Wace LLP acquired a new position in Krystal Biotech during the 4th quarter worth $1,618,000. MetLife Investment Management LLC lifted its position in Krystal Biotech by 4.7% during the 4th quarter. MetLife Investment Management LLC now owns 14,997 shares of the company's stock worth $2,349,000 after acquiring an additional 680 shares during the last quarter. Hsbc Holdings PLC increased its holdings in shares of Krystal Biotech by 195.2% during the 4th quarter. Hsbc Holdings PLC now owns 4,519 shares of the company's stock worth $718,000 after purchasing an additional 2,988 shares during the period. Finally, Voya Investment Management LLC increased its holdings in shares of Krystal Biotech by 5.8% during the 4th quarter. Voya Investment Management LLC now owns 74,701 shares of the company's stock worth $11,703,000 after purchasing an additional 4,123 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on KRYS. Bank of America dropped their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Friday. Chardan Capital dropped their price objective on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday. Citigroup restated a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Guggenheim dropped their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $210.38.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 49,800 shares of company stock valued at $7,487,943 in the last quarter. 13.70% of the stock is owned by insiders.

Krystal Biotech Stock Down 2.5%

NASDAQ KRYS opened at $146.77 on Tuesday. The stock has a market cap of $4.25 billion, a P/E ratio of 29.83 and a beta of 0.70. The company's 50-day simple moving average is $144.50 and its 200 day simple moving average is $154.44. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. Research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.